Earnings of $0.07 per share expected for Cubist Pharmaceuticals Inc (NASDAQ:CBST)'s fourth quarter

Cubist Pharmaceuticals Inc (NASDAQ:CBST)'s forecasted results per share for the fourth quarter ending in December 2014, have seen a roll back by the financial markets and now ranging between $-0.52 and $0.35 per share with a consensus of $0.07 per share.RECOMMENDATIONS

• The consensus recommendation for Cubist Pharmaceuticals Inc (NASDAQ:CBST) is a buy.
• The recommendations from seventeen analysts include three strong buy, eight buy and six hold.
• A buy is the average consensus recommendation for the Ethical Drugs peer group.

FORECAST CHANGES

• Currently, eleven analysts are providing Thomson Reuters I/B/E/S with estimates.
• Over the last week, one estimate was revised up.
• Over the past four weeks, two estimates were revised downward and two upward.
• There has been an addition of one estimate in the past four weeks.
• The consensus earnings per share estimate has fallen from $0.11 per share during the last four weeks.
• Four weeks ago, the high estimate was $0.31 and the low estimate was $-0.20.

YEAR OVER YEAR

• The loss of $0.08 per share earned the same quarter last year is expected to turnaround to a profit of $0.07 per share for the current quarter.
• Earnings for the peer group are expected to decline relative to the corresponding quarter last year and have been revised lower over the last four weeks.

Cubist Pharmaceuticals Inc (CBST) closed yesterday's trading session down 1.40% to $66.40.